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ABSTRACT
Objectives: An abnormal CD4+ T cell subset related to
inflammation exposure (inflammation-related cells, IRC)
has been identified in rheumatoid arthritis (RA). Patients
with inflammatory and non-inflammatory diseases were
used to examine the relationship between inflammation
and this T cell subset in vivo.
Methods: Blood was collected from healthy controls and
patients with RA (active disease or in clinical remission),
Crohn’s disease and osteoarthritis. IRC and chemokine
receptors were quantified by flow cytometry. Thymic
activity and apoptotic factors were measured by real-time
polymerase chain reaction. Circulating cytokines were
measured by enzyme-linked immunosorbent assay.
CXCR4 and SDF1 in synovial biopsies were measured
using immunohistochemistry.
Results: IRC were identified in patients with RA
(p,0.0001) and Crohn’s disease (p = 0.005), but not in
those with osteoarthritis. In RA in remission, IRC persisted
(p,0.001). In remission, hyperproliferation of IRC was
lost, chemokine receptor expression was significantly
lowered (p,0.007), Bax expression dropped significantly
(p,0.001) and was inversely correlated with IRC
(rho =20.755, p = 0.03). High IRC frequency in remis-
sion was associated with relapse within 18 months
(OR = 6.4, p,0.001) and a regression model predicted
72% of relapse.
Conclusions: These results suggest a model in which,
despite the lack of systemic inflammation, IRC persist in
remission, indicating that IRC are an acquired feature of
RA. They have, however, lost their hyper-responsiveness,
acquired a potential for survival, and no longer express
chemokine receptors. IRC persistence in remission
confirms their important role in chronic inflammation as
circulating precursors of pathogenic cells. This was further
demonstrated by much higher incidence of relapse in
patients with high IRC frequency in remission.
Rheumatoid arthritis (RA) is a chronic inflamma-
tory disease of joints and extra-articular tissues,
which results in severe disability and premature
mortality.1 The exact pathogenesis of RA remains
uncertain; however, autoimmune processes are
evidenced by major histocompatibility complex
linkage,2 3 autoantibody production and lympho-
cyte infiltration of the synovial tissue.4 All of these
features support the hypothesis of a T cell driven
disease,5–7 although this ‘‘T centric’’ paradigm has
been challenged.8 9
We recently proposed a model of T cell differ-
entiation and demonstrated divergences in relation
to chronic inflammation in RA.10 Isoforms of the
tyrosine phosphatase CD45 coupled with lymph
node homing receptor CD62L expression, were used
to distinguish ‘‘naı¨ve’’ from ‘‘memory’’ T cells.
Using this model, we demonstrated the presence of
atypical subsets of cells in RA, expressing aberrant
combinations of naı¨ve and memory markers.10 One
subset was characterised by the cell surface expres-
sion of CD45RBhigh CD45RA+ CD45ROlow CD62L–.
We named them inflammation-related cells (IRC),
as the frequency of these cells in the periphery was
directly correlated with systemic levels of inflam-
mation measured by C-reactive protein (CRP).
Retention of CD45RB and CD45RA expression by
IRC, and their relatively high T cell receptor excision
circle (TREC) content compared with naı¨ve cells,
suggested that they were relatively immature and
we postulated that they resulted from inflamma-
tion-driven differentiation and proliferation of naı¨ve
cells.10 They were also hyper-responsive to mitogen
and antigen stimulation.
Cells with a similar phenotype have been
described by other groups. Naı¨ve CD4+ T cells
treated with a combination of interleukin (IL)-2,
IL-6 and tumour necrosis factor (TNF)-a or with
IL-15 developed a phenotype similar to IRC, losing
CD62L but retaining CD45RA and several other
markers of activation.11 12 Activation under similar
conditions induces the expression of chemokine
receptors such as CXCR4,13 suggesting that such
cells are destined to home to sites of inflammation.
RA synovial T cells have been shown to share
many features with cytokine-activated T cells, in
particular with regard to their ability to induce
macrophage production of TNF-a.14
Our current hypothesis is that, following an
initiation phase, T cells in RA are essential to the
perpetuation of the disease in a non-specific way.
Chronic inflammation triggers cytokine T cell
activation independently of antigen. These cyto-
kine-activated T cells express chemokine receptors
and home to inflamed tissue, where they perpetuate
the disease ultimately leading to the destruction of
cartilage and bone. In the current study, we used
several cohorts of patients with RA, inflammatory
and non-inflammatory disease controls and healthy
individuals, to study the relationship between
inflammation and T cell phenotype in vivo.
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MATERIALS AND METHODS
Patient cohorts
Ethical approval was obtained from Leeds Teaching Hospitals
NHS Trust Ethics Committee and informed consent was
obtained from each participant. A number of clinical groups
were studied:
Rheumatoid arthritis cohorts
(1) Patients with active RA (n = 41, age range 20–73 years, CRP
range 10–177 mg/l, 68% rheumatoid factor (RF) positive)
comprised early, disease-modifying anti-rheumatic drug naı¨ve
(n = 22) and long-lasting, refractory RA (n = 19).
(2) RA in clinical remission (n = 42, age range 25–64 years,
57% RF positive). Consultant rheumatologists identified
patients with RA whose disease was in remission. All patients
satisfied the following criteria: (a) RA according to American
College of Rheumatology (ACR) criteria; (b) over 18 years of
age; (c) at least 12 months disease duration; (d) no disease flare
within preceding 6 months; (e) stable therapy for 6 months;
and (f) no clinical indication to change treatment. They had
CRP below 11 mg/l for at least 6 months (median CRP 0, range
0–11 mg/l, with 78% of patients below detectable levels, the
normal CRP range within our local population being 0–10 mg/
l). Disease flare in this cohort was defined by sustained
symptoms of tender or swollen joints, for two or more
consecutive visits, involving more than one site and/or requiring
a change in management (drug or dosage). Owing to the
requirement for high cell numbers, all patients in remission
were analysed for T cell differentiation, but only subsets of this
cohort were used for the other experiments.
(3) Patients with long-lasting, severe RA (n = 12, age range
24–44 years, 75% RF positive) resistant to multiple conven-
tional drugs and who received high-dose chemotherapy (HDC)
followed by autologous haematological stem cell transplanta-
tion (ASCT).15 16 Blood and synovial biopsy samples were
available for analysis at baseline, during clinical remission (1
and 3 months) and at disease flare (9 or 12 months).
Disease controls
(1) Patients with osteoarthritis (OA; n = 12 age range 47–
70 years) fulfilling ACR clinical criteria were recruited, had
established disease with no elevation of CRP (CRP ,10 mg/l).
(2) Patients with active Crohn’s disease (CrD) (n = 13 age
range 18–59 years) had established disease with moderate CRP
(CRP range 5–45 mg/l).
Healthy controls
(1) Healthy controls were recruited from blood donors (n = 49,
age range 24–72 years).
(2) Otherwise healthy individuals with mild cold-like
symptoms, runny nose or sore throat, not requiring medication
(n = 5). Serial samples were obtained during the first 5 days of
symptoms, following resolution (10 days) and 2–3 weeks later.
T cell subset quantification and separation
Naı¨ve, memory and IRC were identified in peripheral blood
mononuclear cells based on their expression of CD45RB (bright
or dull; Dako, Ely, Cambs, UK), CD45RA (+ or 2, Serotec,
Oxford, UK), CD45RO (2, dull or bright, Serotec) and CD62L
(+ or 2, Coulter, High Wycombe, Bucks, UK) as previously
described.10 Cells were further sorted, when required, using a
FACS-Vantage (BD, Oxford, UK) under aseptic conditions.
T cell receptor excision circle measurements
TREC content was measured by real-time polymerase chain
reaction as previously described.17
Proliferation assays
Proliferation assays were performed as described before,10 using
stimulation with phytohaemagglutin (1 and 10 mg/ml, Sigma),
IL-2 (20 units/ml, Sigma), anti-CD3 antibody (OKT3, 1 mg/ml
Ortho Biotech, Bridgewater, NJ, USA) with or without anti-
CD28 antibody (12.5 mg/ml, YTH913 kindly provided by H
Waldmann).
Serum cytokine measurements
TNF-a, IL-2, IL-6 and IL-7 levels in sera were measured by
enzyme-linked immunosorbent assay (R&D Systems,
Abingdon, Oxon, UK) according to the manufacturer’s instruc-
tions. Minimum detection for the assay was 0.5 pg/ml for TNF-
a, 7 pg/ml for IL-2, 0.7 pg/ml for IL-6 and 0.1 pg/ml for IL-7.
Chemokine receptor expression
PE-Cy5 conjugated antibodies (BD) were used to detect cell
surface expression of the chemokine receptors CXCR3, CXCR4
or CCR5 in addition to CD45RB-FITC, CD45RA-PE and
CD62L-ECD.
Bax, Bcl-2 and Bcl-xL expression
Peripheral blood mononuclear cells were lysed and RNA
solubilised as described before and first-strand cDNA was
synthesised using 400 U Superscript II reverse transcriptase
(Invitrogen, Paisley, UK).18 Real-time polymerase chain reaction
was performed using an ABI Prism 7700 sequence detection
system (Applied Biosystems, Warrington, Cheshire, UK) in the
presence of SYBR-green. Primers were designed using Primer
Express (Applied Biosystems). Transcription of the gene of interest
was normalised to that of GAPDH. Primer sequences were:
GAPDH forward: 59-AACAGGGACACCCACTCCTC-39
GAPDH reverse: 59-CATACCAGGAAATGAGCTTGACAA-39
Bcl-2 forward: 59-GTGGAGAGCGTCAACCGG-39
Bcl-2 reverse: 59-GGTTCAGGTACTCAGTCATCCACA-39
Bax forward: 59-GCCACTCCTCTGGGACCC-39
Bax reverse: 59-ACGCATTATAGACCACATCTGATGA-39
Bcl-xL forward: 59-ATACTTTTGTGGAACTCTATGGGAACA-39
Bcl-xL reverse: 59-CGTCAGGAACCAGCGGTT-39.
Immunohistochemistry
Cryostat serial sections of synovial tissue (4 mm) were cut and
dried overnight at 37uC. Sections were fixed in 4% paraformal-
dehyde for 10 min. Endogenous peroxidase was quenched by
treatment with 3% H2O2 for 5 min, followed by pretreatment
with 3% normal serum for 20 min. Sections were incubated at
room temperature for 1 h with specific monoclonal antibodies
to SDF1 and CXCR4 (R&D Systems). An irrelevant isotype-
matched monoclonal antibody acted as a negative control. A
three-stage immunoperoxidase labelling technique incorporat-
ing avidin–biotin-immunoperoxidase complex was used (kit
from Vector Laboratories, Burlingame, CA, USA). Slides were
counterstained with haematoxylin and mounted. Coded slides
were analysed using a semi-quantitative scoring method (0–4),
which has been previously validated19 (0 = no staining, 1 = 1–
25%, 2 = 25–50%, 3 = 50–75%, 4 =.75% staining).
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Statistical analysis
Linear variables were not normally distributed among the
different groups of patients or controls, so non-parametric tests
were used throughout. Medians and ranges were used to
describe data distributions. Spearman’s rank correlation coeffi-
cient was used to correlate two variables. Mann–Whitney U test
was used to compare groups, and the Kruskal–Wallis test was
used for comparisons between more than two independent
samples. p-Values were adjusted for significance according to
number of multiple comparisons performed. Binary logistic
regression was then used to identify dependency between
clinical parameters and laboratory outcomes. For this analysis
continuous variables were dichotomised as below and above
median. Both demographic and clinical variables were entered
individually into a logistic regression model to obtain their
unadjusted odds ratios. Those that were deemed at least
borderline significant (p(0.1) were then entered into a logistic
regression in a step-wise fashion using SPSS version 11. The
variables analysed were: (1) demographics: sex, age; (2) clinical:
disease duration, remission duration, age at disease onset,
satisfying ACR remission criteria,20 21 presence of RF, family
history, past and current drug history, RA complications
(nodules); (3) laboratory: frequency of naı¨ve and IRC CD4+ T
cells, expression of apoptotic factors, levels of circulating
cytokines, expression of chemokine receptors on IRC.
RESULTS
Peripheral CD4+ T cell differentiation pattern in relation to
inflammation
To establish whether factors other than inflammation could
generate IRC, we compared patients with OA and CrD and
otherwise healthy individuals with a mild infection not
requiring medication. In health, very few IRC were observed
in a representative individual (fig 1). IRC were abundant in
active RA as previously described.10 In clinical remission, IRC
remained present. At the cohort level, IRC frequency was high
in active RA compared with healthy controls (table 1, p,0.001)
and remained high in clinical remission (p,0.001). In patients
with OA the differentiation pattern resembled healthy controls
(fig 1), but in CrD it was closer to active RA. IRC frequency was
significantly higher in patients with CrD compared with an age-
matched control (p,0.005). In contrast, the IRC frequency in
OA was not different from that of an age-matched, control
cohort. During the first 5 days of a mild infection, the frequency
of IRC was increased by fivefold compared with a control group
(n = 10, age-matched, data not shown). Following resolution of
symptoms after 10 days, IRC were reduced in the circulation
(less than twofold) and their frequency returned to normal
within 2–3 weeks.
In 12 patients with RA who achieved clinical remission
following HDC and ASCT, we analysed IRC at 1 and 3 months
post-ASCT and in seven patients who had a relapse at 1 year
post-treatment. HDC reduced the number of circulating IRC
(fig 2A, p,0.001); however, between 1 and 3 months IRC
numbers had significantly increased (p,0.001), but the total
number of other CD4+ T cell subsets (naı¨ve, effector and
memory cells) had not.22 The frequency of IRC at relapse was
high and comparable with pretreatment (on average 25% and
27% respectively). A direct relationship between IRC frequency
and CRP was previously observed in patients with active RA,10
and this was also reflected in this group of 12 patients
pretreatment (fig 2B, black circles, rho = 0.682, p = 0.01). A
major reduction in CRP was observed during the remission
period between 1 and 3 months,15 16 and IRC frequency was not
related to CRP at these times (grey and white squares). A trend
toward CRP and IRC frequency being correlated at relapse was
observed (white circles, rho = 0.474, p = 0.133, n = 7).
Proliferation and differentiation from naı¨ve cells
We showed previously that IRC differentiate and proliferate
from naı¨ve cells under the drive of inflammation, resulting in
TREC dilution.10 In patients with RA in remission, in whom we
had previously detected thymic activity,22 the TREC content of
naı¨ve CD4+ T cells was high and within the normal range,
demonstrating an absence of TREC dilution through prolifera-
tion (table 1). These results suggested that there is no
proliferation and differentiation of naı¨ve cells into IRC during
remission. The mechanism by which IRC may differentiate in
remission is, therefore, different from that in active disease.
Cytokine driven proliferation
We investigated the presence of cytokines able to induce the
proliferation of T cells (IL-2, IL-6 and TNF-a11 12) (table 1). IL-6
was below detectable levels in remission and health, and high in
active disease. IL-2 and TNF-a were detected in patients in
remission; however, their presence was not correlated with IRC
frequency. Notably, some of the highest IRC frequencies were
detected in patients with no detectable IL-2 or TNF-a. We used
a regression analysis to predict whether one cytokine could
replace the other or act in combination. The model did not
identify any significant association, confirming our data on
TREC content.
Hyper-responsiveness
IRC were isolated by cell sorting from eight patients from
whom we had obtained samples at times when disease was
active and in remission (fig 3). As shown previously,10 IRC from
samples taken during active disease (grey bars) responded to
mitogen (phytohaemagglutin) and full T cell receptor stimula-
tion (anti-CD3/CD28).10 In contrast, both responses were lost in
remission (black bars). Cells were equally unresponsive to IL-2
and partial T cell receptor stimulation (anti-CD3).
Cell trafficking
We measured the expression of CXCR3, CXCR4 and CCR5 on
CD4+ T cells with an IRC phenotype (table 1). We did not
observe cells with double positivity for any chemokine receptor
and CD62L, confirming that lymph node and tissue homing
were mutually exclusive on IRC. The proportion of chemokine
receptor positive cells with an IRC phenotype was significantly
reduced for all three receptors in remission compared with
active disease (p,0.007 for all).
We next investigated whether cells expressing CXCR4 could
be detected in synovial tissue under conditions of remission. We
also examined the levels of expression of SDF1, one of the
chemokines responsible for attracting T cells to sites of
inflammation. We obtained synovial tissue before HDC
(n = 2), 3 months after ASCT (n = 3), and at relapse
(n = 1).19 23 Strong CXCR4 expression was detected on small
isolated cells in both inflamed tissues (fig 4A), but not in the
tissue obtained when disease was in remission. SDF1 expression
was detected in all samples. SDF1 scores were, however, reduced
in remission compared with baseline and relapse (fig 4B). The
visual analogue score (VAS) for degree of synovitis was recorded
at the time of tissue sampling. A significant correlation between
SDF1 expression and VAS score was observed (rho = 0.784,
p = 0.05).
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Survival drive
We examined the expression of the pro- and anti-apoptotic
factors Bax, Bcl-2 and Bcl-xL (table 1). Owing to the limited
amount of blood available from each participant, we used total
peripheral blood mononuclear cells for this analysis. There was
no difference in expression of the anti-apoptotic factors, Bcl-2
and Bcl-xL, between health, remission and active disease. The
expression of the pro-apoptotic factor Bax was significantly
reduced in remission compared with active disease (p,0.001) or
controls (p,0.001). In addition, there was an inverse relation-
ship between the level of Bax and the frequency of IRC in
remission (rho =20.755, p = 0.030). These data suggest that a
mechanism lowering the expression of Bax may be involved in
the persistence of IRC in remission.
Cytokine rescue is another known mechanism by which T
cells can survive. Having found that there was no effect of IL-2
on IRC frequency, we measured IL-7 (table 1), another known T
cell survival factor. Patients with active RA had significantly less
IL-7 than controls, as previously reported.22 Patients in remission
displayed variable IL-7,22 but there was no relationship between
serum IL-7 levels and IRC frequency in remission.
Prediction of disease flare
Nearly half of the patients in remission (20 of 41) experienced a
disease flare within 18 months of disease cessation. Frequency
of IRC was significantly higher in patients subsequently
relapsing (p = 0.001, OR = 6.4). We therefore analysed factors
that could predict disease flare. We first analysed parameters
individually (table 2). RF positivity (p = 0.041, OR = 3.9) and,
possibly, having nodules (p = 0.121, OR = 3.4) were significant
in predicting relapse. Binary logistic regression analysis revealed
that IRC frequency (p = 0.010, OR = 7.6) and presence of RF
Figure 1 T cell differentiation remains
abnormal in patients with rheumatoid
arthritis (RA) in clinical remission.
Representative flow cytometry plots for a
healthy control (age 48), and a patient
with active RA (age 45), osteoarthritis
(OA, age 60) and Crohn disease (CrD)
(age 45), and a patient with RA in
remission (rem, age 42). CD4+ T cells
were isolated by negative selection using
magnetic beads. Cells were labelled with
antibodies against CD45RB, CD45RA,
CD45RO and CD62L. Cell populations
were first gated according to CD45RB
expression. Plots represent two-colour
analysis of each gated CD45RB bright or
dull population. Inflammation-related cells
(IRC) are CD45RBbright CD45RA+ CD62L2
CD45ROdull (arrows). IRC were present in
the healthy control at a very low
frequency. The differentiation pattern in
the patient with OA resembled the
control. IRC were abundant in the patients
with active RA and CrD, as well as in the
patient with RA in clinical remission.
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(p = 0.046, OR = 4.8) each significantly contributed to the
model. There was no significant further interaction between
these factors. The main effects model was a reasonably good
one, predicting 76% of relapse and 66% of non-relapse (72%
correct, p,0.05), and demonstrated good fit to the data
(Hosmer and Lemeshow test p = 0.989).
DISCUSSION
We previously reported that abnormal differentiation of T cells
in active RA was associated with inflammation, as measured by
CRP.10 We have confirmed these findings in another inflamma-
tory disease, CrD, and longitudinally in RA, and also shown a
similar transient phenomenon in healthy individuals with a
mild infection. Despite a lack of systemic inflammation and
meeting additional clinical criteria for remission, we observed
the persistence of IRC in the circulation of asymptomatic
patients with RA. To explain this persistence, we showed that,
the mechanism by which IRC are generated under inflamma-
tory conditions is different from the mechanism by which they
persist when inflammation is well controlled. We propose that,
IRC in remission are the product of T cell release from synovial
tissue, where they have acquired an increased resistance to
apoptosis. Taken together, these data suggest that the T cell
differentiation abnormalities observed in active disease are a
feature of RA, further amplified by inflammation but ‘‘sus-
pended’’ in remission.
The presence of IRC in remission was unexpected with regard
to our previous work10 and our current longitudinal data
demonstrating a direct relationship between IRC frequency
and CRP in active disease. The frequency of IRC was not
associated with any other parameters. The persistence of IRC in
remission, therefore, suggested different mechanisms for their
emergence (as described before10) and their persistence in
remission. There are several possible explanations for these
observations. Frequency of an individual subset of cells (IRC
among CD4+ T cells) depends on entry, exit, self-renewal or cell
death. Entry may depend on differentiation from another subset
into IRC or, alternatively, entry into the circulation from a
tissue compartment. Exit would imply that IRC are either
differentiating into another circulating subset or exiting the
circulation to enter another tissue compartment. Self-renewal
could be triggered by different stimuli, the most likely being
cytokines. Cell death could be blocked either by cytokine rescue
or other mechanisms specific to the disease. Subclinical
inflammation has been reported in the joint of 96% of patients
in clinical remission using advanced imaging analysis.24 Markers
of systemic inflammation are below or within the normal range
in these patients, but could nevertheless be influential in our
observations. We therefore analysed these parameters in more
detail, comparing active disease and remission.
Chemokines and their receptors are important factors
determining the distribution of T cells within tissue. The
Table 1 IRC frequency, chemokine receptor expression, circulating cytokines and expression of apoptotic
factors (median (range))
IRC frequency
(% of CD4+ T cells) Disease group Control group,* n
Active RA (n = 41) 11.3 (0.7–45) 1.3 (0.1–6.5), n = 30
Remission (n = 41) 9.3 (0.9–32) 1.3 (0.1–6.5), n = 30
OA (n = 12) 11.3 (6.4–30.6) 6.4 (1.2–34.4), n = 20
CrD (n = 13) 9.3 (2.2–14.4) 1.0 (0.9–3.2), n = 20
TREC content{ CD4+ T cells Naı¨ve CD4
Controls (n = 33) 5.7 (1.5–11.0){ 8.0 (2.3–15.0)
Active RA (n = 35) 0.93 (0.05–4.65) 3.35 (0.13–8.96)
Remission (n = 18) 5.15 (1.70–17.80){ 6.4 (1.06–20.11)
Chemokine receptors1 CXCR3 CXCR4 CCR5
Active RA (n = 10) 31.9 (16.4–54) 27.8 (2.4–47) 17.3 (0–66)
Remission (n = 12) 10.7 (2.2–23.5) 4.4 (0–23) 1.0 (0–4.9)
Circulating cytokines"" IL-2" IL-6" TNF-a"
Controls (n = 10) bd (bd-8.8)** bd bd
Active RA (n = 10) bd 13.44 (2.55–16.8) 21 (bd-86){{
Remission (n = 20) bd (bd-40.6){{ bd 1.85 (bd-19.4)11
Circulating cytokines"" IL-7
Controls (n = 10) 13.85 (9.23–22.30)
Active RA (n = 10) 7.0 (2.95–9.83)
Remission (n = 20) 9.02 (2.47–22.85)
Apoptotic factors*** Bax Bcl-2 Bcl-xL
Controls (n = 10) 0.041 (0.02–0.18) 0.053 (0.014–0.32) 0.21 (0.11–0.59)
Active RA (n = 10) 0.045 (0.012–0.19) 0.026 (0.008–0.060) 0.168 (0.07–0.35)
Remission (n = 20) 0.023 (0.007–0.068) 0.034 (0.005–0.18) 0.106 (0.007–0.42)
CrD, Crohn disease; IL, interleukin; IRC, inflammation-related cells; OA, osteoarthritis; RA, rheumatoid arthritis; TREC, T cell
receptor excision circle.
*Disease and control group were aged matched for this analysis. {Measured by real-time polymerase chain reaction as previously
reported17 and {inversely correlated with age.23 1Percentage of cells with an IRC phenotype expressing the receptor. "Cytokines
below detectable level are reported as bd. **Detected in two of 10 controls. {{Detected in eight of 10 patients with active RA.
{{Detected in nine of 20 patients with RA in remission. 11Detected in 13 of 20 patients with RA in remission. ""Measured by
enzyme-linked immunosorbent assay (pg/ml of serum). ***Measured by real-time polymerase chain reaction and normalised to
GAPDH.
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chemokine/receptor pair SDF-1/CXCR4 has been shown to be
important for the accumulation of T cells in synovial tissue in
RA.25 Our results show that tissue homing is not sustained on
IRC in remission (table 1). As IRC are also not differentiating de
novo in remission, this suggests that the factors inducing
expression of chemokine receptors on their surface are now
missing. In support of this hypothesis, we showed previously
that CD4+ T cell infiltration, particularly of CD4+ T cells with a
CD45RA+ phenotype, was significantly reduced in biopsies
from patients responding to HDC.19 In contrast, CD8+ T cells, B
cells, macrophages and natural killer cells remained in the tissue.
We also showed that SDF-1 expression in the synovium is
reduced in remission, but comparable with baseline at relapse.
We further demonstrated that small cells expressing CXCR4 are
detected in synovial tissue in active disease, but not in
remission. Our data therefore suggest that IRC are destined to
home to tissues in active disease, but not in remission when
they recirculate.
The proliferation and hyper-responsiveness of IRC in active
disease were not present in the absence of systemic inflamma-
tion. Similar cells were observed transiently in otherwise
healthy individuals with a mild infection. This suggested that,
either a defect in the regulation of cell death at the end of an
infectious/inflammatory episode, or the presence of an uni-
dentified survival/growth factor may participate in the patho-
genesis of RA, by maintaining cells that should otherwise have
died. IL-2, IL-7 and other cc cytokines are known to induce T
cell survival by upregulating the Bcl-2 and Bcl-xL anti-apoptotic
factors,26 but our results do not support such a mechanism.
Cell–cell contact-dependent interaction with stromal cells
results in an environmental blockade of apoptotic cell death in
synovial T cells in RA.27–29 Survival through the downregulation
of Bax expression may be a novel mechanism by which
(stromal) factors in the synovium reduce T cell susceptibility
to apoptosis.
Altogether our results point to a lack of effect of inflamma-
tion on the features of IRC in remission that are associated with
these cells in active disease. The DAS28 score and CRP level,
which are measures of disease activity, were not associated with
IRC frequency. A need to reach a threshold of inflammation, in
order to activate the ‘‘bad side’’ of IRC (hyper-responsiveness,
chemokine receptor expression), could explain our results. The
non-fulfilment of this requirement would reflect the absence of
systemic inflammation. On the other hand, our data could also
be explained by a subclinical inflammatory drive to the
differentiation of IRC. The higher frequency of IRC in patients
in remission destined for relapse could reflect subclinical
inflammation, which has been identified in this cohort using
highly sensitive imaging techniques.24 Therefore, the current
work extended our imaging findings by providing a circulating
biomarker predictive of relapse.
While not implicating T cells as primary pathogenic players,
our data are consistent with such a model. We showed
previously that IRC develop in the periphery from naı¨ve T
cells, non-specifically under the drive of inflammation.10 We
showed in this study that IRC in active disease express
chemokine receptors, which may drive them to relocate to the
inflamed synovium. The movement of IRC in and out of the
synovium would, however, be biased towards exit in remission,
releasing IRC into the circulation. T cell survival factors
expressed in the synovium may alter the local balance of pro-
and anti-apoptotic factors.25 28 31 IRC, which have been primed
Figure 2 Inflammation-related cell (IRC) frequency correlates with C-
reactive protein (CRP) in active disease but not in remission. (A)
Following high-dose chemotherapy and autologous haematological stem
cell transplantation, the number of IRC (black bars) post-treatment was
greatly reduced (compare pretreatment with 1 month, p,0.001). During
remission, IRC numbers increased (compare 1 and 3 months remission,
p,0.001), but total cells numbers (grey bars) did not increase
significantly. At time of relapse (1 year) IRC frequency reached
pretreatment levels in terms of ratio to total numbers. (B) In the same
patients, a relationship between CRP and IRC frequency was observed
pretreatment (black circles rho = 0.682, p = 0.014), but was lost at
1 month (grey squares). During the remission period (white squares) IRC
numbers increased; however, no relationship with CRP was observed. At
relapse (white circles, seven of 12 patients) the CRP-IRC frequency
relationship was apparent, but not significant (rho = 0.465, p = 0.133).
Figure 3 Inflammation drives the hyper-responsiveness of immature
atypical cells. CD4+ T cells were separated and labelled as described in
fig 1 and further sorted under aseptic conditions according to their
inflammation-related cell phenotype. Proliferation in response to mitogen
(phytohaemagglutin (PHA) 10 mg/ml), interleukin (IL)-2 (20 units/ml) and
T cell receptor stimulation (anti-CD3 1 mg/ml and anti-CD28 5 mg/ml)
was measured using a 3H-thymidine incorporation assay ((CPM) after
5 days in culture (20 000 cells/well)). Samples collected during active
disease are represented by grey bars and samples collected during
remission by black bars. Hyper-responsiveness to PHA and full T cell
receptor stimulation of inflammation-related cells in active disease was
not observed in remission.
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towards survival in the synovium, can therefore persist in the
periphery, until a new inflammatory episode triggers them to
initiate relapse. Thus, these cells are a potential tool for
monitoring a patient’s response to treatment. In addition,
treatments that reduce joint inflammation (such as TNF
blockade) allowing the release of potentially pathogenic cells
(such as IRC) into the circulation, followed by treatments that
would kill these cells specifically, may provide new therapeutic
avenues to be explored.
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